Incannex Healthcare Has Commenced A Phase 2 Trial To Assess The Safety And Efficacy Of Its Proprietary Anti-inflammatory Combination Drug IHL-675A For Rheumatoid Arthritis
IHL-675A is a proprietary fixed-dose combination drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ).